Does Aetna Cover Saxenda? Brand, Generic, and 2026–2027 Rules

Does Aetna cover Saxenda? Sometimes. Your plan has to include weight-loss drugs first. On Aetna's public 2026 Standard Plan drug list (updated October 1, 2026), brand Saxenda is a non-preferred brand (NPB), while generic liraglutide for weight management is listed as a generic (G). Novo Nordisk is discontinuing brand Saxenda, with last shipments to wholesalers in late January 2027.

That means "covered" on a public list is not the same as "your plan will pay," and brand Saxenda is the wrong long-term bet even when a request goes through. Below: how Aetna treats brand vs generic, the prior-authorization rules in Aetna's own bulletins, what the discontinuation changes, and when a weekly GLP-1 is the more realistic next step.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

RX Index Decision Verdict: Confirm whether your Aetna plan covers weight-loss drugs at all, then search both "Saxenda" and "liraglutide" on your member drug tool before you fill brand Saxenda.

Best for: Adults on commercial Aetna who already have a Saxenda or weight-loss liraglutide prescription, or who need to know what happens before January 2027.

Not ideal for: Anyone whose Summary of Benefits excludes weight-loss drugs, and Medicare members looking for Saxenda on the GLP-1 Bridge (it isn't there).

The factor that matters most: Whether weight-loss drugs are a covered benefit on your Aetna plan. Prior authorization can't add a benefit your plan left out.

We can't see your ID card or promise your copay. What we can do is show Aetna's public rules, dated November 5, 2026, and the exact questions that get you a real answer.

Aetna and Saxenda at a glance

Three terms, once:

• Formulary: your plan's drug list.
• Prior authorization (PA): a permission slip from Aetna. Your doctor's office sends records; Aetna decides before it pays.
• Benefit exclusion: the plan leaves weight-loss drugs out. That is different from a missing-paperwork denial.

If you'd rather start with a weekly option your plan may already prefer, Ro's free checker phones your insurer about the Ozempic, Wegovy, and Zepbound pens — not Saxenda — and emails a coverage report. Ro says the check does not submit a treatment request or write a prescription.

Not sure which path fits yet? The RX Index's Find My GLP-1 Path tool is free, takes about 2 minutes, and needs no signup. You can start it here.

Brand Saxenda vs generic liraglutide on Aetna

Aetna's public Standard Plan Pharmacy Drug Guide distinguishes the products clearly. Brand SAXENDA is NPB. The lowercase entry liraglutide -weight management (same 18 mg/3 mL pen strength) is G. Wegovy pens, Wegovy tablets, Wegovy HD, Qsymia, Foundayo, and Zepbound pens sit on the preferred-brand (PB) side of that antiobesity section.

A January 30, 2026 Aetna letter about April 1, 2026 Standard Plan changes put this in writing: Saxenda moved from preferred to non-preferred, with preferred alternatives listed as liraglutide, orlistat, Qsymia, and Wegovy. So if a pharmacy rejects brand Saxenda but shows "liraglutide," that can be a product-tier issue — not proof your benefit is gone.

Two catches matter:

1. Which liraglutide? There is a weight-management generic of Saxenda, and there are diabetes liraglutide products related to Victoza. Ask the pharmacist: "Is this the liraglutide for weight management, the generic of Saxenda?"
2. Listing ≠ payment. Aetna's own formulary and employer GLP-1 pages say the member's benefit plan decides coverage, and many plans exclude weight-loss drugs even when a drug appears on a public list.

FDA approved Teva's liraglutide injection as a first generic of Saxenda (ANDA 214568). Additional weight-management liraglutide ANDAs also appear in Drugs@FDA (including Biocon 217063 and Orbicular 217234). Your plan's tool is still the source of truth for which NDC it will pay.

For a broader multi-insurer view of brand vs generic coverage trends, see our Saxenda insurance coverage guide. For Aetna's preferred weekly option, see does Aetna cover Wegovy.

What brand Saxenda's discontinuation means for Aetna members

Novo Nordisk says it is discontinuing Saxenda, with last shipments to wholesalers in late January 2027. It says the decision is not because of any safety or quality concern. FDA's shortage database lists Saxenda (NDC 0169-2800-15) as limited availability, with the same January 2027 discontinuation wording (last updated September 22, 2026 on the Current listing we opened).

That is a shipping date, not the day every pharmacy shelf goes empty. In practice:

• If you're starting now: ask whether the weight-management generic, or a preferred weekly drug such as Wegovy, fits your chart and your Aetna list better than brand Saxenda.
• If you're already on brand Saxenda: talk with your prescriber before stock gets tight. Bring your starting weight and your latest weight — Aetna's continuation rules use those numbers.
• If you're renewing: ask which product your approval covers (brand vs generic) and when it ends. Adult initial approvals in the bulletins below last 4 months.

This page does not give switching or dosing instructions. Your clinician decides any change in medicine. For head-to-head context, see Saxenda vs Ozempic and Wegovy vs Zepbound vs Saxenda.

What Aetna requires to approve Saxenda

Aetna publishes more than one non-Medicare pharmacy bulletin that can apply. Your plan documents, not a blog post, decide which one you are under. Two public ones we opened on November 5, 2026:

Both bulletins require documentation for BMI (or pediatric weight) and say that if you switched from another weight-loss drug, Aetna looks at your baseline from the start of any weight-loss drug therapy — not only your weight the day the new request is filed.

Do not use if you or a family member has had medullary thyroid cancer (MTC), or if you have MEN 2. Saxenda's label carries that contraindication and a boxed warning about thyroid C-cell tumors seen in rodents. The label also warns about pancreatitis and says to stop when pregnancy is recognized. A licensed clinician decides whether Saxenda is appropriate for you.

How to check your own Aetna Saxenda coverage

1. Read your Summary of Benefits and Coverage for a weight-loss or anti-obesity drug exclusion.
2. Log in to your Aetna member site or use Aetna's Find a Medication tool. Search Saxenda and liraglutide.
3. Call the pharmacy number on your ID card and ask: "Does my plan cover weight-loss drugs? Is brand Saxenda covered or non-preferred? Is weight-management liraglutide covered? Does it need prior authorization, and what is my cost after the deductible?"
4. Ask which PA policy ID applies (for example 1227-C or 6450-C). Write down the answer.
5. If brand is NPB, ask whether your plan prefers generic liraglutide, Wegovy, Qsymia, or another listed alternative — matching Aetna's April 2026 change letter.

Still stuck on a step-therapy or preferred-drug maze? Our how to bypass step therapy with Aetna page walks the exception path in plain words. For preferred GLP-1 ranking on Aetna lists, see best GLP-1 on Aetna formulary.

What Saxenda costs with Aetna — and without it

With coverage, you pay your plan's copay or coinsurance after any deductible. We can't publish a single Aetna Saxenda copay because it varies by employer, deductible, and tier (NPB vs G). Non-preferred brands usually cost more than generics or preferred brands when both are covered.

Without coverage, Novo Nordisk lists Saxenda at $1,349.02 for the five-pen package (about 30 days at 3 mg daily). The manufacturer savings card is closed to new patients (June 30, 2023; remaining activated benefits ended December 31, 2023).

Generic liraglutide for weight management at Mark Cuban Cost Plus Drugs was $716.50 per five-pen box with the dispensing fee, or $771.50 shipped, in stock when we queried Cost Plus's pricing API on November 5, 2026. Teva publishes a commercial copay card for its generic ("as little as $20," expires December 31, 2026) only when your commercial plan covers that product; government-program enrollees and cash-pay patients are excluded. Full price detail lives on our Saxenda cost page.

Weekly cash options are often lower than brand Saxenda's list price. Novo's Wegovy self-pay offer, as of November 5, 2026, starts at $199 a month for the first two months at 0.25 mg or 0.5 mg for new patients, then $349 a month (Wegovy HD 7.2 mg is $399). Ro posts matching cash prices for Wegovy and Zepbound and bills membership separately ($39 the first month, then $74 to $149 a month depending on plan length). Ro's Saxenda page does not post a Saxenda cash price.

For cash comparisons without Aetna, see cheapest Wegovy without insurance, Ro GLP-1 cost, and cheapest GLP-1 without insurance. Alternatives after brand Saxenda ends are collected in best Saxenda alternatives.

If Aetna says no

Match the denial to the problem:

For Marketplace-style internal appeals, HealthCare.gov describes filing within 180 days of the denial notice and, if needed, an external review. Employer plans can follow different ERISA clocks — use the deadline on your denial letter.

If brand Saxenda is a dead end, Ro's free checker can still report whether your plan covers a weekly pen (Wegovy, Zepbound, or Ozempic). Ozempic is not FDA-approved for weight loss; Aetna's diabetes rules for it are separate — see does Aetna cover Ozempic. Ro says patients with Medicaid and some other government-funded plans aren't eligible for treatment on Ro.

Medicare, Medicaid, and other Aetna plans

Medicare: The temporary Medicare GLP-1 Bridge (from July 1, 2026) covers Foundayo, Wegovy (injection or tablet), and the Zepbound KwikPen only, at a $50 monthly copay for eligible people with Part D coverage. Saxenda and its generic are not on that Bridge list. Ask your Aetna Medicare drug plan whether any supplemental weight-loss benefit exists outside the Bridge. More detail: Aetna Medicare Advantage GLP-1 coverage and Medicare GLP-1 Bridge program.

Medicaid / Aetna Better Health: Rules are state-specific and often stricter. One public example we opened: Aetna's Michigan Medicare HIDE (HMO D-SNP) Medicaid weight-loss criteria PDF lists both Saxenda and "liraglutide (generic for Saxenda)" as non-preferred GLP-1s behind a long preferred non-GLP-1 trial path. That document is not a national Medicaid rule — check your state's list.

Other insurers: For comparison, see does Cigna cover Saxenda and does Blue Cross Blue Shield cover Saxenda. Aetna Wegovy PA detail is at Aetna Wegovy prior authorization.

What we actually verified

All checks were done on November 5, 2026.

• We opened Aetna's 2026 Standard Plan Pharmacy Drug Guide (October 1, 2026 update) and confirmed Saxenda = NPB and liraglutide weight management = G, with Wegovy/Qsymia/Foundayo/Zepbound on PB in the antiobesity section.
• We read Aetna's April 1, 2026 Standard Plan change letter naming Saxenda's move to non-preferred and its preferred alternatives.
• We read pharmacy clinical bulletins 1227-C and 6450-C end to end (BMI bars, 6-month program, 16-week / 4% renewal, quantity limits, approval lengths).
• We re-checked NovoCare's discontinuation notice, Saxenda's prescribing information (revised February 2026), the $1,349.02 list price, FDA's liraglutide shortage API, and FDA first-generic / Drugs@FDA records for Saxenda generics.
• We queried Cost Plus Drugs' pricing API for weight-management liraglutide ($716.50 / $771.50 shipped) and opened Teva's copay-card PDF.
• We opened Ro's pricing, insurance, coverage-checker, and Saxenda pages. Ro's claims are its own; we did not test phone calls to Aetna.
• We could not confirm: your personal copay, which PA bulletin your employer bought, whether every Aetna Medicaid state mirrors Michigan's HIDE PDF, or Cost Plus's HTML product page (bot wall; API worked). We also could not re-open the STEP 8 trial abstract today (publisher blocks), so this page does not quote those percentages.

Frequently asked questions

Does Aetna cover Saxenda?

Sometimes. Your plan must include weight-loss drugs, and you must meet its prior-authorization rules. On Aetna's public 2026 Standard Plan list, brand Saxenda is non-preferred (NPB).

Does Aetna cover generic Saxenda (liraglutide)?

The same Standard Plan list marks liraglutide for weight management as a generic (G). Aetna's April 2026 change letter named liraglutide as a preferred alternative when Saxenda moved to non-preferred. Confirm the product is the weight-management generic, not a diabetes liraglutide.

What BMI does Aetna require for Saxenda?

It depends which bulletin your plan uses. Public bulletin 1227-C uses adult BMI ≥30, or ≥27 with a weight-related condition. Public bulletin 6450-C uses adult BMI ≥35 for its combined GLP-1 weight-loss pathway. Ask member services which policy ID applies.

Is Saxenda being discontinued?

Yes. Novo Nordisk says last shipments to wholesalers are in late January 2027, and that the decision is not about safety or quality. FDA's shortage listing carries the same January 2027 timing for brand Saxenda.

How long does an Aetna Saxenda approval last?

Under the reviewed adult bulletins, first approval is 4 months. Continuation can run 12 months when the 16-week and 4% weight-loss (or maintenance) rules are met and documented.

Can I still use a Saxenda savings card with Aetna?

No new Saxenda manufacturer savings enrollments have been allowed since June 30, 2023. Teva offers a separate commercial copay card for its generic when your plan covers that product; it expires December 31, 2026 under the PDF we opened.

Does Medicare cover Saxenda through Aetna?

The Medicare GLP-1 Bridge does not include Saxenda or its generic. Check your Aetna Medicare drug benefit for any other weight-loss coverage and read our Aetna Medicare GLP-1 guide.

Can Ro check my Saxenda coverage for free?

No. Ro's free checker covers the Ozempic, Wegovy, and Zepbound pens, not Saxenda. Use it if you are comparing weekly options; use your Aetna member tools for Saxenda itself.

Still not sure which GLP-1 path fits you? Take The RX Index's free Find My GLP-1 Path quiz — about 2 minutes, no signup.

Sources

All sources checked November 5, 2026.

• Aetna 2026 Standard Plan Pharmacy Drug Guide (formulary update stamped 10/01/2026)
• Aetna Standard Plan drug-list changes beginning April 1, 2026 (letter dated January 30, 2026)
• Aetna Pharmacy Clinical Policy 6450-C: Weight Loss (BMI 35) GIP-GLP-1 / GLP-1 Agonists PA with Limit (08-2025 v11)
• Aetna Pharmacy Clinical Policy 1227-C: Saxenda PA with Limit (P08-2024_R)
• Aetna Find a Medication and Aetna formulary hub
• Aetna Medical Clinical Policy Bulletin 0039: Weight Reduction Programs and Devices
• Aetna: GLP-1 benefit coverage (employers)
• Aetna Better Health / Michigan HIDE Medicaid weight-loss PA criteria PDF
• NovoCare: Saxenda discontinuation and savings-offer status
• Novo Nordisk: Saxenda list price
• Saxenda prescribing information (revised February 2026)
• FDA drug shortages API: liraglutide
• FDA 2025 first generic drug approvals (ANDA 214568, Saxenda); Drugs@FDA: 214568, 217063, 217234
• Cost Plus Drugs: liraglutide weight management (price confirmed via Cost Plus pricing API November 5, 2026)
• Teva liraglutide injection copay card PDF (May 2026 update)
• Wegovy coverage and savings
• Medicare.gov: weight-loss drugs / GLP-1 Bridge; Bridge $50 fact sheet PDF
• HealthCare.gov: internal appeals and external review
• Ro: pricing, insurance, GLP-1 Insurance Coverage Checker, Saxenda